All articles tagged with #autoimmune diseases
A 47-year-old German woman with refractory autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome was treated with CAR-T cell therapy to eradicate rogue B cells and reboot her immune system. After exhausting standard therapies, this radical approach led to dramatic improvement and is described by doctors as a landmark in immunotherapy.
A 47-year-old woman with autoimmune haemolytic anaemia (AIHA), immune thrombocytopenia (ITP) and antiphospholipid syndrome (APS) achieved rapid, lasting remission after CD19-targeted CAR-T cell therapy, effectively resetting her immune system and enabling a near-normal life; she has remained in treatment-free remission for about 14 months, while researchers note the need for trials to determine durability and wider applicability.
Endometriosis is described as a systemic immune disorder driven by chronic inflammation, with elevated cytokines such as IL-6 and IL-1beta in the blood and immune cells that fail to clear lesions, producing ripple effects like fatigue, brain fog, and widespread pain beyond pelvic symptoms. A 2025 study linked endometriosis to roughly twice the odds of an autoimmune diagnosis within two years of onset, suggesting shared inflammatory mechanisms rather than a purely reproductive disease; reframing it as a whole-body immune condition could guide development of immune-modulating treatments and empower patients in healthcare settings.
Gilead Sciences will acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestones to add OM336, a BCMAxCD3 T cell engager, to its inflammation portfolio. OM336 has shown single‑cycle efficacy in autoimmune diseases such as AIHA and ITP and holds Fast Track and Orphan Drug designations with registrational studies expected in 2027. Gilead is also pursuing a strategic collaboration with Galapagos on Ouro assets, with Galapagos covering half of upfront and milestone payments, sharing development costs, and receiving 20%–23% royalties on net sales while Gilead retains worldwide commercialization rights (except Greater China). The deal aims to advance immune-reset therapies by depleting pathogenic B cells/plasma cells to reduce inflammation, potentially enabling durable drug‑free remission; regulatory and integration risks remain.
Gilead Sciences agreed to buy Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestones to add OM336, a BCMAxCD3 T cell engager, to its inflammation portfolio. OM336 has shown rapid B cell depletion with a favorable safety profile in Phase 1/2 data and has FDA Fast Track and Orphan Drug designations, with registrational studies expected in 2027. Gilead is also in advanced talks for a collaboration with Galapagos, under which Galapagos would fund half of upfront and milestone payments, absorb Ouro’s operating assets, and receive 20-23% royalties on net sales while Gilead retains worldwide commercialization rights. The combined effort aims to accelerate immune-reset therapies for autoimmune diseases and potentially deliver durable, drug-free remission through BCMA-targeted T cell engagers.
A CART4-34 CAR-T therapy targets the IGHV4-34 gene in B-cell cancer, destroying lymphoma cells in mice as effectively as CD19 CAR-T while sparing healthy B cells and avoiding immune suppression; the approach could also be used to treat autoimmune conditions such as lupus, but human trials are needed.
Scientists have discovered that a small subset of maternal immune cells persist in offspring throughout life, actively maintaining immune tolerance to maternal cells and potentially influencing various health conditions, including autoimmune diseases, cancer, and neurological disorders.
The article discusses the complexities of autoimmune diseases like lupus, highlighting recent scientific advances such as CAR-T therapy and targeted drugs, which offer hope for better diagnosis, understanding, and treatment of these conditions that affect millions worldwide.
Autoimmune diseases, which can affect nearly every part of the body and are more common in women, occur when the immune system mistakenly attacks healthy tissues. There are over 100 such diseases, with symptoms ranging from mild to life-threatening, and diagnosis can be complex. Recent research offers hope for more targeted treatments and early interventions, with ongoing clinical trials showing promising results. The global market for autoimmune treatments is substantial, reflecting the widespread impact of these chronic conditions.
Autoimmune diseases, which can affect various parts of the body and are more common in women, occur when the immune system mistakenly attacks healthy tissues. They are difficult to diagnose due to vague symptoms and overlapping conditions, but new research and clinical trials are exploring treatments that aim to reprogram the immune system and delay disease onset. Despite advances, treatment remains complex and often lifelong, with ongoing efforts to improve diagnosis and develop targeted therapies.
Ruth Wilson's six-year struggle to diagnose her lupus highlights the challenges of autoimmune diseases, which affect millions and are difficult to treat. Advances in research, including new therapies like CAR-T and targeted drugs, offer hope for better diagnosis, understanding, and potentially cures, as scientists explore the complex biology and diverse subtypes of these conditions.
The article discusses the revolutionary potential of mRNA technology for treating cancer, genetic diseases, and autoimmune conditions, highlighting how US federal policies are currently hindering its development and application, risking a setback in biomedical innovation and international competitiveness.
Fred Ramsdell, a Whitefish immunologist, won the 2025 Nobel Prize in Physiology or Medicine for his work on regulatory T cells and immune tolerance, which has significant implications for treating autoimmune diseases and cancer. His journey from community college to Nobel laureate highlights his passion for impactful science and serendipitous career path, with recent advancements enabling clinical applications of his research.
A Portland-born molecular biologist, Mary E. Brunkow, along with two other scientists, won the Nobel Prize in medicine for discovering how regulatory T cells help prevent autoimmune diseases by maintaining immune system balance, a breakthrough that could lead to better treatments for conditions like diabetes and lupus.
Three scientists, Mary E. Brunkow, Fred Ramsdell, and Dr. Shimon Sakaguchi, won the Nobel Prize in medicine for their discoveries related to peripheral immune tolerance, particularly the role of regulatory T cells and the Foxp3 gene in controlling immune responses and preventing autoimmune diseases.